Impax Labs Receives AP Status for Tetracycline Hydrochloride ANDA060469
Impax Labs has received an Abbreviated Approval (AP) for their ANDA060469 submission for Tetracycline Hydrochloride.
Asset / Drug
Drug and asset intelligence for Impax with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.